top 10 drug in 21 century

7/30/2019 Top 10 Drug in 21 Century

1/4

SEND TOPRINTER

Page 1 of 4

11/15/2012http://www.genengnews.com/keywordsandtools/print/3/29343/


2/4

mostmedicinecabinets.

It seems like you can't turn on your television or your computer nowadays without seeing another advertisement fora new prescription medicine, complete with an invitation to "ask your doctor if it's right for you!" Of these, manysome with a little help from serendipitygo on to great success. GEN has put together a list of the top 10 best-selling drugs between 2000 and 2011, based on sales figures disclosed by companies marketing the drugs in annualreports, quarterly press releases, and other publicly available materials. Are any of these in your medicine chest?

#10. Humira (adalimumab)1

$32.044 billion

Abbott Laboratories

Approved 2002; Launched 2003; U.S. patent expires December 2016

2011: $7.932 billion

2010: $6.548 billion

#9. Lovenox (enoxaparin)

$33.069 billion

Sanofi2

Approved 1993; Launched 1993; U.S. patent found unenforceable in 2009 by U.S.Supreme Court, which upheld lower court finding of inequitable conduct by Sanofi basedon arguments by generic drug makers Amphastar Pharmaceuticals and TevaPharmaceutical Industries

2011: $2.737 billion (2.111 billion)

2010: $3.637 billion (2.806 billion)

#8. Seroquel (quetiapine fumarate)

$36.652 billion

AstraZeneca

Approved 1997; Launched 1997 (Seroquel IR) and 2007 (Seroquel XR); U.S. patentexpired September 2011, followed by a six-month pediatric extension that ended inMarch 2012

2011: $5.828 billion$4.338 billion (IR) + $1.490 billion (XR)

2010: $5.302 billion$4.148 billion (IR) + $1.154 billion (XR)

#7. Singulair (montelukast)

$38.466 billion

Merck & Co.

Approved 1998; Launched 1999; U.S. patent expired August 2012

2011: $5.479 billion

2010: $4.987 billion

#6. Nexium (esomeprazole)

$44.336 billion

AstraZeneca

Approved 2000; Launched 2001; U.S. patent expires May 2014

Page 2 of 4



3/4

#5. Enbrel (etanercept)

$45.168 billion

Page 3 of 4



4/4

2012 Genetic Engineering & Biotechnology News, All Rights Reserved

Notes:

1 For 2005, 2007, and 2008, Abbott materials available online included sales figures that were rounded off to a single digit.

2 Figures up to 2003 were released by predecessor Aventis, which developed the drug; conversion from Euros on Oct. 31, 2012 via xe.com.

3 Does not include a share of alliance revenue, which Pfizer only reported at the lump sum $3.630B though it consists of sales from Enbrel and four other drugs.

4 GlaxoSmithKline figures converted from British pounds on Nov. 1, 2012 via xe.com.

5 Global sales are the sum of sales recorded by Bristol-Myers Squibb (BMS) and Sanofi. Figures up to 2003 were released by Sanofi predecessor Sanofi-Synthlabo. Sanofi

figures converted from Euros on Nov. 1, 2012 via xe.com.

Page 4 of 4

11/15/2012http://www genengnews com/keywordsandtools/print/3/29343/

top 10 drug in 21 century

Documents